---
title: Iambic Therapeutics (IAM) Eyes $150 Million IPO to Advance AI-Designed Cancer Therapies
description: Pharma partnerships and early HER2 trial results underpin the offering, but rising development costs and an unproven pipeline keep clinical execution at the center of the investment case.
image: https://blog.ipoprophet.com/hubfs/Iambic%20Thumbnail.jpg
---

[Skip to content](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/iambic-therapeutics-iam-eyes-150-million-ipo-to-advance-ai-designed-cancer-therapies#main-content)

[![IPO\_PROPHET\_BLUE logo](https://blog.ipoprophet.com/hs-fs/hubfs/IPO_PROPHET_BLUE%20logo.png?width=2973&height=302&name=IPO_PROPHET_BLUE%20logo.png)](https://www.IPOProphet.com)

- [Login](https://app.ipoprophet.com/login)

Open main navigation

Close main navigation

- [Login](https://app.ipoprophet.com/login)

[Subscribe to our Newsletter](https://share.hsforms.com/1xXldKrGiQBCbNmtOz6j4Jwq3cu4)

[Go Back to Home](http://www.ipoprophet.com/)

[Go Back to Blog](http://www.ipoprophet.com/blog)

 Oct 9, 2026, 2:37:00 PM

# Iambic Therapeutics (IAM) Eyes $150 Million IPO to Advance AI-Designed Cancer Therapies

![Picture of Eric Friedman](https://app.hubspot.com/settings/avatar/7a4cca62b5a89282b41a283a43efa80e) [Eric Friedman](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/author/eric-friedman)

Share: [facebook-f icon](http://www.facebook.com/share.php?u=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/iambic-therapeutics-iam-eyes-150-million-ipo-to-advance-ai-designed-cancer-therapies) [linkedin-in icon](http://www.linkedin.com/shareArticle?mini=true&url=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/iambic-therapeutics-iam-eyes-150-million-ipo-to-advance-ai-designed-cancer-therapies) [Twitter icon](https://twitter.com/intent/tweet?url=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/iambic-therapeutics-iam-eyes-150-million-ipo-to-advance-ai-designed-cancer-therapies) [pinterest-p icon](http://pinterest.com/pin/create/link/?url=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/iambic-therapeutics-iam-eyes-150-million-ipo-to-advance-ai-designed-cancer-therapies) [envelope icon](mailto:?body=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/iambic-therapeutics-iam-eyes-150-million-ipo-to-advance-ai-designed-cancer-therapies)

![Iambic Logo](https://blog.ipoprophet.com/hs-fs/hubfs/Iambic%20Logo.jpg?width=289&height=108&name=Iambic%20Logo.jpg)

**Iambic Therapeutics (IAM)**, a San Diego-based biotechnology company combining artificial intelligence with automated laboratory research, is preparing to offer **9.375 million shares** on the **Nasdaq Global Select Market** at **$15–$17 per share**. At the **$16 midpoint**, the offering would raise **$150 million in gross proceeds** and imply a **post-offering market capitalization of approximately $758.4 million**. **J.P. Morgan, Jefferies, BofA Securities, and Citigroup** are the joint book-running managers. The preliminary prospectus does not specify a final pricing or trading date.

Iambic is seeking to turn AI-assisted drug discovery into both a wholly owned therapeutic pipeline and a source of pharmaceutical collaboration revenue. Its platform combines models that predict molecular properties and protein interactions with automated chemistry and biological testing. The goal is to shorten the cycle of designing, making, and testing potential medicines while using laboratory results to improve the models. Its principal AI technologies include Enchant and NeuralPLexer. The company calls this approach “molecular superintelligence,” but acknowledges that the platform has not yet produced an approved drug.

The lead program, IAM1363, is an oral HER2 inhibitor being evaluated in an ongoing Phase 1/1b trial in patients with advanced HER2-altered solid tumors. Iambic is developing the molecule to target a range of HER2 mutations while limiting activity against wild-type EGFR, a feature intended to improve tolerability. Its ability to penetrate the brain could also be relevant for patients with brain metastases. Potential indications include breast cancer, non-small cell lung cancer, and gastroesophageal cancer. The company anticipates initiating a registrational trial as early as 2027, subject to regulatory feedback.

Early clinical results provide an initial signal of activity, although they remain preliminary. In the August 31, 2026 data extract, 19 of 53 efficacy-evaluable patients with targetable HER2 alterations and measurable systemic disease who received 960 mg daily or higher achieved a best overall partial response, or 36%. The confirmed objective response rate was lower, at 23%, representing 12 of 53 patients. Among 22 response-evaluable patients with measurable central nervous system disease, four had confirmed responses, for a confirmed intracranial response rate of 18%. These results come from an exploratory, open-label study that was not designed to establish superiority over existing treatments, and further follow-up could change the findings.

Two additional oncology programs could broaden the pipeline. IAM217 is a brain-penetrant KIF18A inhibitor intended for ovarian cancer, triple-negative breast cancer, and other solid tumors. Iambic submitted its investigational new drug application on September 30, 2026 and plans to begin a Phase 1/2 trial subject to regulatory clearance. IAM-C1, a selective dual CDK2/CDK4 inhibitor, is expected to reach an IND submission in the fourth quarter of 2026, followed by a planned Phase 1/2 trial, also subject to clearance. Neither program has established efficacy in human trials.

![Iambic Image 1](https://blog.ipoprophet.com/hs-fs/hubfs/Iambic%20Image%201.jpg?width=858&height=285&name=Iambic%20Image%201.jpg)

Pharmaceutical partnerships give Iambic a second route to monetizing its technology. Its agreements include collaborations with Takeda, Lundbeck, Revolution Medicines, and, beginning in September 2026, AbbVie. The Takeda relationship combines small-molecule discovery with access to NeuralPLexer, while AbbVie’s agreement initially covers two targets and includes options to license resulting compounds. These arrangements can provide upfront fees, research funding, milestones, and potential royalties, but future milestone and royalty payments depend on successful development and commercialization. NVIDIA is also an investor and technology partner, adding to the company’s AI profile without removing the clinical risks inherent in drug development.

![Iambic Image 2](https://blog.ipoprophet.com/hs-fs/hubfs/Iambic%20Image%202.jpg?width=880&height=285&name=Iambic%20Image%202.jpg)

Collaboration revenue increased from $1.2 million in 2024 to $9.4 million in 2025, then reached $12.8 million in the first half of 2026, up approximately 225% from $3.9 million a year earlier. First-half revenue included approximately $6.2 million from Takeda, $4.2 million from Lundbeck, and $2.4 million from Revolution Medicines. These are collaboration revenues, not sales of approved medicines, and recognition can fluctuate with research progress and contractual milestones. Iambic has no approved products and does not expect product-sales revenue for several years, if ever.

Spending is rising substantially as the pipeline advances. Research and development expense totaled $77.5 million in 2025 and $57.1 million in the first half of 2026, compared with $32.9 million in the prior-year half. Net losses widened from $47.9 million in 2024 to $77.3 million in 2025, and from $33.2 million to $50.1 million between the first halves of 2025 and 2026. Operating cash outflow was $58.8 million in 2025 and $24.9 million in the first half of 2026. Collaboration funding helps support operations, but revenue remains well below development and administrative costs.

Iambic held $207.9 million in cash and cash equivalents at June 30, 2026 and subsequently raised $66.5 million through convertible notes expected to convert into equity in connection with the IPO. At the midpoint, estimated net IPO proceeds are $135 million. The prospectus presents pro forma adjusted cash of approximately $409.4 million after the note financing and offering; that figure adjusts the June 30 balance sheet and does not reflect subsequent operating cash usage. Management expects available cash and net offering proceeds to fund operations into or through the fourth quarter of 2028, although that projection depends on its operating assumptions.

![Iambic Financial Placard](https://blog.ipoprophet.com/hs-fs/hubfs/Iambic%20Financial%20Placard.jpg?width=826&height=550&name=Iambic%20Financial%20Placard.jpg)

The company plans to allocate approximately $75 million of offering proceeds and existing cash to IAM1363, $15 million each to IAM217 and IAM-C1, and $20 million to continued platform development, with the remainder for working capital and general corporate purposes. Underwriters have an option to purchase another 1.406 million shares, which would increase gross proceeds to $172.5 million at the midpoint. ARK Investment Management and Duquesne Family Office have expressed nonbinding interest in purchasing up to $60 million combined, equivalent to 40% of the base offering at the midpoint. Actual purchases could differ, but participation at that level would reduce the shares available to other investors.

The investment case rests on whether Iambic can convert its technology, partnerships, and early clinical signals into durable therapeutic value. Partnership revenue provides external commercial validation of the platform, while the IPO would strengthen funding for several development milestones. The principal risks remain early-stage clinical uncertainty, competition from established and emerging oncology treatments, reliance on a small group of collaboration partners, and continued losses that could eventually require additional financing. At roughly $758 million in midpoint equity value, investors would be paying primarily for future pipeline and platform potential rather than an established drug business.

 

[IPOs](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/ipos), [2026](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/2026), [Iambic Therapeutics](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/iambic-therapeutics)

[linkedin-in icon](https://www.linkedin.com/company/ipo-prophet-software/) [X Twitter icon](https://www.x.com/ipoprophet)

---

[![IPO\_PROPHET\_WHITE-2](https://blog.ipoprophet.com/hs-fs/hubfs/IPO_PROPHET_WHITE-2.png?width=800&height=250&name=IPO_PROPHET_WHITE-2.png "IPO_PROPHET_WHITE-2")](http://www.ipoprophet.com)

NONE OF THE CONTENT PUBLISHED ON THE WEBSITE OR MOBILE APP CONSTITUTES A RECOMMENDATION, SOLICITATION, ENDORSEMENT, OR OFFER BY IPO PROPHET™ OR ITS AFFILIATES TO BUY OR SELL ANY SECURITIES, FUTURES, OPTIONS, OR OTHER FINANCIAL INSTRUMENTS, OR PROVIDE ANY INVESTMENT ADVICE OR SERVICE.

Copyright © 2025

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Eric Friedman",
    "url" : "https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/author/eric-friedman"
  },
  "dateModified" : "2026-10-09T18:37:00.097Z",
  "datePublished" : "2026-10-09T18:37:00.000Z",
  "headline" : "Iambic Therapeutics (IAM) Eyes $150 Million IPO to Advance AI-Designed Cancer Therapies",
  "image" : [ "https://blog.ipoprophet.com/hubfs/Iambic%20Thumbnail.jpg" ],
  "mainEntityOfPage" : {
    "@id" : "https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/iambic-therapeutics-iam-eyes-150-million-ipo-to-advance-ai-designed-cancer-therapies",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://blog.ipoprophet.com/hubfs/IPO_PROPHET_BLUE%20logo-1.png"
    },
    "name" : "ipoprophet.com"
  }
}
```